Tag: Pharmaceutical Industry

Bayer
Healthcare
Germany

Valuation Analysis: Bayer AG

Bayer shows operational progress in the second quarter of 2026. Crop Science and new pharmaceutical products are strengthening the recovery,
Active icon
Continue Umbrella
Bayer
Healthcare
Germany

Stock: Bayer AG

Bayer is operationally improving its earnings position. However, high debt, weak cash flow, and legal risks are slowing the stock's
Active icon
Continue Umbrella
Johnson & Johnson
Healthcare
USA

Valuation Analysis: Johnson & Johnson

Johnson & Johnson is one of the world's leading healthcare companies. The company benefits from a strong position in pharmaceuticals
Active icon
Continue Umbrella
Johnson & Johnson
Healthcare
USA

Stock: Johnson & Johnson

Thanks to a strong pipeline, robust cash flows and a defensive business model, Johnson & Johnson remains a high-quality healthcare
Active icon
Continue Umbrella
Eli Lilly
Healthcare
USA

Stock: Eli Lilly and Company

Eli Lilly is one of the leading pharmaceutical companies worldwide. Growth drivers include Mounjaro, Zepbound, and a strong pipeline in
Active icon
Continue Umbrella
Company Update

Bayer: Valuation Update After the Latest Price Recovery

Bayer after the latest price recovery: new developments in legal risks, analyst expectations, and the technical picture complement the valuation.
Continue Umbrella
Company Update

MUMAK SpotLight of the week: Eli Lilly and Palantir in focus

Eli Lilly strengthens its pipeline, Palantir remains volatile, and Johnson & Johnson gains momentum. The most important developments of the
Continue Umbrella
Company Update

RED HOT CHILI™ MUMAK of the Week: Johnson & Johnson – Breakout Drawing Closer?

Johnson & Johnson shows operational strength and a constructive chart picture. The resistance at $273–274 now comes into focus.
Continue Umbrella
Company Update

RED HOT CHILI MUMAK of the Week: Johnson & Johnson – Technical Chart Picture Brightens Significantly

Following strong quarterly figures, a raised annual guidance, and a further improvement in the chart setup, Johnson & Johnson receives
Continue Umbrella